Skip to Main Content
Table 1.

Effect of docetaxel on splenic cell populations

CellsTreatmentPretreatmentTime posttreatment
Day 1Day 2Day 3Day 4Day 7
Splenocytes PBS 1.1 × 108  1.4 × 108  1.1 × 108  1.1 × 108  9.6 × 107  1.1 × 108  
 Docetaxel —  8.1 × 107  7.4 × 107  8.6 × 107  1.1 × 108  1.1 × 108  
CD4+ PBS 18% 2.0 × 107 17% 2.4 × 107 18% 2.0 × 107 17% 1.9 × 107 15% 1.4 × 107 25% 2.8 × 107 
 Docetaxel —  19% 1.5 × 107 19% 1.4 × 107 19% 1.6 × 107 10% 1.1 × 107 19% 2.1 × 107 
CD8+ PBS 13% 1.4 × 107 11% 1.5 × 107 8% 8.8 × 106 10% 1.1 × 106 9% 8.6 × 106 14% 1.5 × 107 
 Docetaxel —  13% 1.0 × 107 14% 1.0 × 107 12% 1.0 × 107 7% 7.7 × 106 13% 1.4 × 107 
CD19+ PBS 60% 6.6 × 107 62% 8.7 × 107 64% 7.0 × 107 58% 6.4 × 107 52% 5.0 × 107 61% 6.7 × 107 
 Docetaxel —  54% 4.4 × 107 58% 4.3 × 107 52% 4.5 × 107 40% 4.4 × 107 49% 5.4 × 107 
DX5+ PBS 2.8% 3.1 × 106 2.7% 3.7 × 106 2.4% 2.6 × 106 2.5% 2.8 × 106 2.0% 1.9 × 106 3.4% 3.7 × 106 
 Docetaxel —  2.7% 2.2 × 106 2.5% 1.8 × 106 2.2% 1.9 × 106 1.8% 2.0 × 106 4.4% 4.8 × 106 
Tregs PBS 5% 5.5 × 106 4.0% 5.6 × 106 8.8% 9.7 × 106 7.2% 7.9 × 106 8.1% 7.8 × 106 7.3% 8.0 × 106 
 Docetaxel —  6.7% 5.4 × 106 11.5% 8.5 × 106 9.5% 8.2 × 106 9.2% 1.0 × 107 8.5% 9.4 × 106 
CellsTreatmentPretreatmentTime posttreatment
Day 1Day 2Day 3Day 4Day 7
Splenocytes PBS 1.1 × 108  1.4 × 108  1.1 × 108  1.1 × 108  9.6 × 107  1.1 × 108  
 Docetaxel —  8.1 × 107  7.4 × 107  8.6 × 107  1.1 × 108  1.1 × 108  
CD4+ PBS 18% 2.0 × 107 17% 2.4 × 107 18% 2.0 × 107 17% 1.9 × 107 15% 1.4 × 107 25% 2.8 × 107 
 Docetaxel —  19% 1.5 × 107 19% 1.4 × 107 19% 1.6 × 107 10% 1.1 × 107 19% 2.1 × 107 
CD8+ PBS 13% 1.4 × 107 11% 1.5 × 107 8% 8.8 × 106 10% 1.1 × 106 9% 8.6 × 106 14% 1.5 × 107 
 Docetaxel —  13% 1.0 × 107 14% 1.0 × 107 12% 1.0 × 107 7% 7.7 × 106 13% 1.4 × 107 
CD19+ PBS 60% 6.6 × 107 62% 8.7 × 107 64% 7.0 × 107 58% 6.4 × 107 52% 5.0 × 107 61% 6.7 × 107 
 Docetaxel —  54% 4.4 × 107 58% 4.3 × 107 52% 4.5 × 107 40% 4.4 × 107 49% 5.4 × 107 
DX5+ PBS 2.8% 3.1 × 106 2.7% 3.7 × 106 2.4% 2.6 × 106 2.5% 2.8 × 106 2.0% 1.9 × 106 3.4% 3.7 × 106 
 Docetaxel —  2.7% 2.2 × 106 2.5% 1.8 × 106 2.2% 1.9 × 106 1.8% 2.0 × 106 4.4% 4.8 × 106 
Tregs PBS 5% 5.5 × 106 4.0% 5.6 × 106 8.8% 9.7 × 106 7.2% 7.9 × 106 8.1% 7.8 × 106 7.3% 8.0 × 106 
 Docetaxel —  6.7% 5.4 × 106 11.5% 8.5 × 106 9.5% 8.2 × 106 9.2% 1.0 × 107 8.5% 9.4 × 106 

NOTE: C57BL/6 mice (n = 5 per group) were given 0.5 mg docetaxel i.p. on days −4, −2, and 0. Control mice received PBS only. Mice were sacrificed 1, 2, 3, 4, and 7 d posttreatment. After lysis of RBC, splenocytes were counted and stained for T cells (CD3+, CD4+, CD8+), B cells (CD19+), natural killer cells (DX5+), and Tregs (CD4+CD25+FoxP3+). Of the CD4+cells that expressed CD25, >98% also stained positive for FoxP3. Cells were analyzed by flow cytometry. Percentages denote the percent of splenocytes. Bold numbers indicate a significant difference (P < 0.05) in docetaxel versus PBS treated mice. This experiment was repeated twice.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept